BRAIN and NERVE－神経研究の進歩67巻10号

2015年10月発行

総説 シリーズ・ビタミンと神経疾患その2

アスコルビン酸（ビタミンC）とシャルコー・マリー・トゥース病

著者： 能登祐一¹

所属機関： ¹京都府立医科大学大学院医学研究科神経内科学

ページ範囲：P.1241 - P.1246

文献概要

2004年のPassageらによるCMT1Aモデルマウスに対するアスコルビン酸投与の有効性の報告を契機に，欧米において，5つのランダム化比較試験が行われた。アスコルビン酸は既にヒトでの安全性が確認されており，Passageらの報告はCMT1A治療のブレークスルーにつながるものと期待されたが，ヒトでの結果は異なるものであった。本稿では，これまでの臨床試験の歴史とその結果，今後の治療の展望につき概説する。

参考文献

1) Rossor AM, Polke JM, Houlden H, Reilly MM: Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 9: 562-571, 2013

2) Young P, De Jonghe P, Stogbauer F, Butterfass-Bahloul T: Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev CD006052, 2008

3) Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, et al: Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10: 396-401, 2004

4) Huxley C, Passage E, Robertson AM, Youl B, Huston S, et al: Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hu Mol Genet 7: 449-458, 1998

5) Saberan-Djoneidi D, Sanguedolce V, Assouline Z, Levy N, Passage E, et al: Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 248: 223-231, 2000

6) Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, et al: Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 17: 248-253, 2007

7) Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, et al: Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 7: 70, 2009

8) Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, et al: Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 8: 537-544, 2009

9) Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, et al: Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 8: 1103-1110, 2009

10) Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, et al: Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10: 320-328, 2011

11) Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, et al: Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 70: 378-383, 2008

12) Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, et al: High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 70: 981-987, 2013

13) Weber P, Bendich A, Schalch W: Vitamin C and human health--a review of recent data relevant to human requirements. Int J Vitam Nutr Res. 66: 19-30, 1996

14) Thomas PK, Marques W Jr, Davis MB, Sweeney MG, King RH, et al: The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120 (Pt 3): 465-478, 1997

15) Burns J, Ouvrier R, Estilow T, Shy R, Laura M, et al: Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 71: 642-652, 2012

16) Visioli F, Reilly MM, Rimoldi M, Solari A, Pareyson D; for the CMT-TRIAAL ＆ CMT-TRAUK Groups: Vitamin C and Charcot-Marie-Tooth 1A: pharmacokinetic considerations. PharmaNutrition 1: 10-12, 2013

17) Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, et al: AAV1．NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther 22: 511-521, 2014